Efficacy of sulfadoxine-pyrimethamine, amodiaquine, and sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated falciparum malaria in the urban and suburban areas of Brazzaville (Congo).

摘要: Abstract Congo-Brazzaville has recently adopted artesunate-amodiaquine as the first-line antimalarial drug to replace chloroquine. Before implementation of this new strategy, we conducted several clinical studies assess therapeutic efficacy former, classical drugs in city Brazzaville, which reside about 30% Congolese population. From 2003 2005, non-randomised trials were evaluate sulfadoxine-pyrimethamine (SP) ( n  = 97 patients), amodiaquine (AQ)  = 62 and combination sulfadoxine-pyrimethamine–amodiaquine  = 54 patients) children aged between 6 months 5 years with uncomplicated malaria using WHO guidelines during 28-day follow-up period. After excluding infections by PCR, proportion treatment failure on day 28 was 30.2% (95% confidence interval, 19.2–43.0%) for sulfadoxine-pyrimethamine, 34.8% 21.4–50.2%) amodiaquine, 14.2% 5.9–27.2%) sulfadoxine-pyrimethamine + amodiaquine combination. Treatment associated an increase gametocyte charge. These results suggest that neither nor is efficacious monotherapy their may not remain effective coming years. Based our results, artemisinin-based therapy appears be urgent country.